Last Updated: November 16, 2026

ZILRETTA Drug Patent Profile

« Back to Dashboard


Which patents cover Zilretta, and when can generic versions of Zilretta launch?

Zilretta is a drug marketed by Pacira Pharms Inc and is included in one NDA. There are two patents protecting this drug.

The generic ingredient in ZILRETTA is triamcinolone acetonide. There is one drug master file entry for this compound. Eighty suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zilretta

A generic version of ZILRETTA was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1st, 1986.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for ZILRETTA?
  • What are the global sales for ZILRETTA?
  • What is Average Wholesale Price for ZILRETTA?
Summary for ZILRETTA
Recent Clinical Trials for ZILRETTA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Walter Reed National Military Medical CenterPHASE2
Pacira Pharmaceuticals, IncPHASE2
University of Kansas Medical CenterPHASE4

See all ZILRETTA clinical trials

US Patents and Regulatory Information for ZILRETTA

ZILRETTA is protected by two US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pacira Pharms Inc ZILRETTA triamcinolone acetonide FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR 208845-001 Oct 6, 2017 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Pacira Pharms Inc ZILRETTA triamcinolone acetonide FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR 208845-001 Oct 6, 2017 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Zilretta Market Dynamics, Financial Trajectory, Patent Protection and Generic Risk

Last updated: November 10, 2026

Zilretta, Pacira BioSciences’ extended-release triamcinolone acetonide injection, has developed into a mid-sized specialty pharmaceutical franchise with annual sales generally in the low-to-mid hundreds of millions of dollars. Its commercial value comes from differentiated drug delivery, physician-office reimbursement, and repeat use in knee osteoarthritis. Its main risks are premium pricing, payer controls, competition from conventional corticosteroid injections and hyaluronic-acid products, and potential ANDA-based generic entry after key patent barriers weaken.

What is Zilretta and how does it compete?

Zilretta is an extended-release injectable suspension of triamcinolone acetonide for intra-articular administration in the management of osteoarthritis pain of the knee. The product uses Flexion Therapeutics’ microsphere-based poly lactic-co-glycolic acid, or PLGA, delivery system to extend corticosteroid exposure in the joint.

The FDA approved Zilretta in October 2017 under the 505(b)(2) pathway. Flexion developed the product, and Pacira acquired Flexion in 2021 for approximately $1.8 billion, adding Zilretta to its Exparel-focused non-opioid pain portfolio (Pacira BioSciences, 2022).

Product Active ingredient Delivery Primary use Commercial owner
Zilretta Triamcinolone acetonide Extended-release intra-articular microspheres Knee osteoarthritis pain Pacira BioSciences
Kenalog-40 and generics Triamcinolone acetonide Immediate-release injection Multiple inflammatory conditions Multiple manufacturers
Synvisc-One Hyaluronan Single-dose intra-articular injection Knee osteoarthritis Sanofi
Durolane Hyaluronic acid Single-dose intra-articular injection Knee osteoarthritis Bioventus
Monovisc Hyaluronic acid Single-dose intra-articular injection Knee osteoarthritis Anika Therapeutics
Corticosteroid generics Various corticosteroids Immediate-release injection Joint pain and inflammation Multiple manufacturers

Zilretta’s clinical and commercial differentiation is duration of local effect. The product is administered as a 32 mg injection and is not interchangeable with conventional triamcinolone acetonide injections. The label is limited to knee osteoarthritis and does not establish approval for shoulder, hip or other joints (U.S. Food and Drug Administration, 2017).

What is the financial trajectory of Zilretta?

Zilretta has remained a meaningful Pacira revenue contributor, although Exparel is the company’s larger commercial asset. Pacira’s acquisition of Flexion converted Zilretta from a standalone growth product into a component of a broader non-opioid pain platform.

Financial period Zilretta commercial position Key driver
2017-2019 Launch and formulary development New product adoption and physician education
2020 Pandemic-related procedure disruption Lower elective orthopedic volume
2021 Pacira acquisition Expanded sales infrastructure and contracting
2022-2023 Established specialty product Repeat use, buy-and-bill access and broader physician adoption
2024 onward Mature growth asset Volume growth offset by payer scrutiny and price pressure

Pacira’s public filings reported Zilretta net product sales in the approximate $130 million to $150 million annual range in the early 2020s. The product’s revenue profile is materially smaller than Exparel but large enough to support Pacira’s operating leverage, sales force utilization and orthopedic franchise strategy (Pacira BioSciences, 2023, 2024).

The acquisition economics were based on more than Zilretta’s immediate revenue. Flexion also supplied manufacturing know-how, physician relationships and intellectual property around extended-release corticosteroid delivery. Pacira’s investment case depended on sustained Zilretta cash flow, expansion into additional joints or indications, and cross-selling with Exparel and iovera°.

What factors could increase Zilretta revenue?

Revenue growth depends primarily on unit expansion rather than major price increases. The most important commercial drivers are:

  1. Increased use by orthopedic surgeons, rheumatologists and pain specialists.
  2. Higher diagnosis and treatment rates for knee osteoarthritis.
  3. Expanded use in ambulatory surgical centers and physician offices.
  4. Favorable payer coverage under Medicare Part B and commercial medical benefits.
  5. Conversion from repeated immediate-release corticosteroid injections.
  6. Potential label expansion into other joints or indications.

The principal constraint is the premium relative to generic triamcinolone. Zilretta must demonstrate sufficient duration and clinical utility to justify higher acquisition cost, administration cost and payer review.

How does Zilretta reimbursement affect its market position?

Zilretta is administered by healthcare professionals and is generally reimbursed through the medical benefit rather than the pharmacy benefit. This buy-and-bill structure gives physicians control over product selection but creates working-capital, inventory and reimbursement requirements.

The product uses a dedicated Healthcare Common Procedure Coding System code, J3304, for triamcinolone acetonide extended-release injectable suspension. Reimbursement is affected by Medicare payment rules, average sales price reporting, commercial payer contracts and site of care.

Reimbursement factor Effect on Zilretta
Dedicated J-code Improves billing specificity and reduces coding ambiguity
Medical-benefit coverage Supports office and outpatient administration
Average sales price methodology Can limit price expansion
Prior authorization Delays use and increases administrative burden
Step therapy May require failure of conventional steroid or hyaluronic acid
Buy-and-bill model Creates margin opportunity but requires inventory funding
Site-of-care migration Can alter reimbursement and physician economics

Payer policies often require documentation of knee osteoarthritis, prior conservative treatment and failure or inadequate response to lower-cost alternatives. These controls can reduce rapid uptake even when physicians prefer the product’s longer duration.

What patents protect Zilretta?

Zilretta’s protection is based on formulation, drug-delivery and composition-of-matter claims rather than a new chemical entity patent for triamcinolone acetonide. The active ingredient has been used for decades, so the commercial moat depends on the extended-release microsphere platform and product-specific manufacturing process.

Representative Zilretta-related U.S. patent families include:

Patent family General subject matter Commercial relevance
U.S. Patent No. 8,852,598 Extended-release corticosteroid formulation and delivery Foundational formulation protection
U.S. Patent No. 9,974,773 Long-acting injectable corticosteroid compositions Supports product-specific formulation claims
Later continuation and improvement patents Particle characteristics, release profile and manufacturing parameters Can extend claim coverage beyond the earliest patent

The effective protection period depends on patent-term adjustment, terminal disclaimers, Orange Book listings, claim scope and the outcome of any ANDA litigation. Patent expiry cannot be determined from the original approval date alone.

The most defensible intellectual-property claims are those directed to the combination of:

  • Triamcinolone acetonide;
  • Biodegradable PLGA microspheres;
  • Specific particle-size distributions;
  • Controlled release over an extended period;
  • Injectable suspension characteristics; and
  • Manufacturing steps that produce the required release profile.

Manufacturing claims can be important because a competitor may find it difficult to copy the commercial product while avoiding formulation and process claims. That protection is less secure if an ANDA applicant develops a different microsphere process with materially different composition and release characteristics.

What is the Orange Book status of Zilretta?

Zilretta is an FDA-approved small-molecule injectable drug, not a biologic. The relevant generic pathway is an abbreviated new drug application, or ANDA, rather than a biosimilar application.

The FDA Orange Book is the controlling source for listed patents, expiration dates and any pediatric-exclusivity adjustments. Zilretta’s listed protection has historically centered on formulation and delivery patents, not the underlying triamcinolone molecule (U.S. Food and Drug Administration, n.d.).

Because Orange Book listings and patent-term calculations can change through patent corrections, delistings, litigation outcomes and regulatory updates, the commercial entry date must be assessed against the live listing at the time of an ANDA filing.

When does Zilretta lose exclusivity?

Zilretta did not receive five-year new chemical entity exclusivity because triamcinolone acetonide was already approved. The product received regulatory protection associated with a new dosage form and clinical investigation under the 505(b)(2) framework. That type of exclusivity is shorter than NCE exclusivity and does not prevent all competing applications indefinitely.

The principal long-term barrier is patent protection. The foundational patent estate began expiring in the early 2030s, while later continuation patents may extend selected claims further, potentially into the mid-to-late 2030s depending on validity and enforceability.

Exclusivity layer Expected role
505(b)(2) clinical-investigation exclusivity Short-term protection after approval
Formulation patents Primary protection for the extended-release product
Manufacturing patents Protection against process-based copying
Trade secrets Protection for scale-up and particle engineering
Trademark protection Brand protection but no barrier to an approved generic
Regulatory labeling Limits competing products that rely on the same clinical information

Which companies could challenge Zilretta?

Potential challengers include established generic injectable manufacturers and specialty injectable developers with microsphere or depot-formulation capabilities. Relevant categories include:

  • Teva Pharmaceutical Industries;
  • Sandoz;
  • Viatris;
  • Amneal Pharmaceuticals;
  • Hikma Pharmaceuticals;
  • Fresenius Kabi;
  • Eugia Pharma Specialties; and
  • Specialized contract developers pursuing 505(b)(2) or ANDA products.

A conventional triamcinolone generic does not automatically substitute for Zilretta. A challenger would need to obtain approval for an extended-release product with comparable pharmaceutical characteristics, labeling and substitutability status.

What Paragraph IV risks exist for Zilretta?

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable or not infringed. Pacira could file an infringement action within 45 days, triggering a statutory stay of FDA approval for up to 30 months, subject to court action and regulatory exceptions.

Challenge stage Commercial effect
Paragraph IV notice Signals possible early generic entry
45-day patent suit window Determines whether automatic stay is triggered
30-month stay Delays FDA approval in many cases
District-court litigation Tests claim construction, validity and infringement
Settlement May create a negotiated entry date
Final FDA approval Does not always mean immediate commercial launch

A Paragraph IV challenge would focus on obviousness, written description, enablement, claim construction and whether the proposed generic falls within the asserted particle and release-profile claims. The manufacturing claims may be more difficult to evaluate because infringement can depend on confidential process details.

No broad biosimilar risk applies. Zilretta is not a biologic and does not have a biosimilar pathway under the Public Health Service Act.

What patent litigation and settlement risks affect Zilretta?

The central litigation risk is an ANDA case against a generic injectable manufacturer. The financial impact would depend on whether the challenger seeks:

  • A declaration of invalidity;
  • Non-infringement;
  • A license with an agreed entry date;
  • A formulation that avoids the Orange Book claims; or
  • A court decision after the 30-month stay.

An authorized generic is also a possible commercial response, although Pacira would need to assess manufacturing economics, channel effects and any settlement restrictions.

Publicly disclosed litigation should be reviewed through Pacira’s Securities and Exchange Commission filings, district-court dockets and FDA Orange Book updates. A settlement can preserve near-term revenue but often reduces the long-term value of the patent estate by setting an earlier agreed entry date.

How strong is the Zilretta patent estate?

The estate is stronger than a basic repurposed-drug portfolio because it covers a differentiated delivery system. It is weaker than a new chemical entity estate because the active ingredient is old and generic triamcinolone is widely available.

Strength Assessment
Active ingredient Weak, because triamcinolone is long established
Formulation Stronger, if claims cover critical microsphere attributes
Release profile Potentially strong, but vulnerable to obviousness attacks
Manufacturing process Useful if difficult to design around
Clinical differentiation Supports commercial value but does not itself prevent copying
Patent duration Material through the 2030s, subject to claim validity
Substitution risk Moderate, because immediate-release products are cheaper

The estate’s commercial strength depends on whether a generic can produce equivalent extended-release performance without using the claimed formulation architecture. The greater the technical distance between Zilretta and a conventional steroid injection, the more relevant the formulation patents become.

How does Zilretta compare with Exparel?

Zilretta and Exparel are both Pacira products based on extended-release drug delivery, but they address different markets.

Factor Zilretta Exparel
Active ingredient Triamcinolone acetonide Bupivacaine
Main use Knee osteoarthritis pain Postsurgical and regional analgesia
Primary customer Orthopedic and pain physicians Surgeons, hospitals and ambulatory centers
Reimbursement Medical benefit, office and outpatient Medical benefit, hospital and outpatient
Generic threat Extended-release triamcinolone ANDA Extended-release bupivacaine competition
Commercial role Specialty outpatient franchise Pacira’s core revenue product

Zilretta provides Pacira with exposure to chronic musculoskeletal pain, while Exparel is tied more closely to surgical volumes and perioperative protocols.

What generic launch scenarios exist for Zilretta?

Three scenarios are commercially relevant.

Scenario 1: No early generic launch

Pacira maintains Zilretta revenue through the remaining patent term. Growth is driven by physician adoption, payer access and repeat administration. This is the highest-value outcome for the company.

Scenario 2: Negotiated entry

A challenger receives a license for an agreed future date. Revenue declines more gradually, but Pacira loses some terminal patent value and may face preparatory payer contracting by the generic entrant.

Scenario 3: Litigation defeat or successful design-around

A generic launches after FDA approval and patent clearance. Price erosion could be substantial because triamcinolone itself is inexpensive and payers have an economic incentive to favor the lower-cost alternative. Zilretta could retain a premium segment if physicians value duration, convenience or reduced injection frequency.

What is Zilretta’s geographic coverage?

Zilretta’s strongest commercial position is in the United States, where FDA approval, dedicated coding and established buy-and-bill reimbursement support adoption. International opportunities are limited by:

  • Separate regulatory filings;
  • Country-specific reimbursement;
  • Local pricing controls;
  • Different osteoarthritis treatment guidelines;
  • Limited willingness to pay for premium intra-articular corticosteroids; and
  • Potentially weaker patent coverage outside the United States.

The U.S. market therefore remains the primary source of Zilretta value. Foreign patent families and regulatory approvals should be assessed country by country rather than assumed from U.S. rights.

Key Takeaways

  • Zilretta is a differentiated extended-release triamcinolone product for knee osteoarthritis.
  • Pacira acquired the product through its approximately $1.8 billion purchase of Flexion Therapeutics in 2021.
  • Annual Zilretta sales have generally been in the low-to-mid hundreds of millions of dollars.
  • The commercial model depends on physician-office administration, J-code reimbursement and medical-benefit coverage.
  • The primary intellectual-property protection covers formulation, microsphere characteristics, release profile and manufacturing.
  • Zilretta is exposed to ANDA-based generic risk, not biosimilar risk.
  • The underlying triamcinolone molecule provides little protection; the formulation estate carries most of the value.
  • Patent protection is expected to remain commercially relevant through the 2030s, subject to Orange Book status, patent-term adjustments and litigation.
  • Generic entry could produce meaningful price erosion because conventional triamcinolone is inexpensive.
  • Pacira’s financial exposure is material but smaller than its Exparel exposure.

FAQs

Is Zilretta a biologic drug?

No. Zilretta is a small-molecule injectable suspension containing triamcinolone acetonide. Any competing product would generally proceed through an ANDA or, depending on its design, a 505(b)(2) application.

Can generic triamcinolone replace Zilretta?

Not automatically. Immediate-release triamcinolone products are not equivalent to Zilretta’s extended-release formulation and do not provide the same labeled product characteristics.

Does Zilretta have five-year new chemical entity exclusivity?

No. Triamcinolone acetonide was previously approved. Zilretta’s regulatory protection was based on its new formulation and clinical development rather than new chemical entity status.

What is the main commercial risk to Zilretta?

The main risk is payer-driven substitution toward lower-cost conventional corticosteroids, followed by formulation-specific generic entry once patent barriers weaken.

Why did Pacira acquire Flexion Therapeutics?

Pacira acquired Flexion to obtain Zilretta, its extended-release corticosteroid platform, commercial infrastructure and related intellectual property. The transaction expanded Pacira beyond perioperative analgesia into chronic musculoskeletal pain.

References

Pacira BioSciences, Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission.

Pacira BioSciences, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.

Pacira BioSciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.

U.S. Food and Drug Administration. (2017). Zilretta prescribing information. U.S. Department of Health and Human Services.

U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

U.S. Patent No. 8,852,598. (2014). Extended-release corticosteroid compositions and methods of use.

U.S. Patent No. 9,974,773. (2018). Extended-release injectable corticosteroid formulations.

More… ↓

⤷  Start Trial

DrugChatter Q&A for ZILRETTA

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.